Bausch + Lomb Corporation: Spin-Off Ready To Fly Troubled Nest And Find Upside
Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuticals. Bausch + Lomb's CEO, the veteran Pharma dealmaker Brent Saunders, has praised the performance of the existing business and hinted at a focus on existing products and targeting growth.
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C.
